FDA knocks back King Pharmaceuticals self-injectible epilepsy product

NewsGuard 100/100 Score

King Pharmaceuticals, Inc. has reported the receipt by its Meridian Technologies subsidiary of a letter from the U.S. Food and Drug Administration advising the Company that its Abbreviated New Drug Application (“ANDA”) regarding King’s diazepam-filled auto-injector therapy for the emergency treatment of status epilepticus and severe recurrent convulsive seizures associated with epilepsy is not approvable.

The FDA raised concerns regarding whether the product, a self-injectible therapy, is appropriate for self-diagnosis and use. King is currently evaluating how best to satisfy the concerns raised by the FDA with the intent of amending or resubmitting the application.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
World's first human mini-brain with a fully functional blood-brain barrier developed